PANA project bases its approach on the importance of researching in early pathophysiological processes of Alzheimer’s disease (AD) using nanotechnology. Currently, there is not an effective method for the early diagnosis of AD. Therefore, there is an urgent need to develop new effective early diagnostic and therapeutic strategies to help in delaying the appearance of the most adverse symptoms of this disease, the leading cause of dementia and loss of autonomy in the elderly, involving a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in next decades. PANA project has received funding from the EU’s Horizon 2020 research and innovation programme, and includes an exclusive consortium which combines neuroscientists, nanotechnologists, molecular imaging experts, clinicians and small/medium/large enterprises in an effort to provide new very-early diagnostic tools for AD, a vital medical/social problem in EU. STAB VIDA, Investigação e Serviços em Ciências Biológicas is a Portuguese certified biotech small-medium enterprise established in 2001, with a dedicated line of products and services for genetics, genomics and immunology. Its main R&D interests for commercialization are focused in point-of-care diagnostics and theragnostics (mainly for Alzheimer’s, Lyme and Cancer diseases), oligo synthesis, bioinformatics and nucleic acid sequencing, including next-generation sequencing, for the biotechnology and biomedical research and clinical community. Currently, STAB VIDA’s sales territory is mainly spread throughout Portugal, Spain, UK, Italy, South America and Africa, including a client portfolio of more than 20 clinical diagnostic laboratories/centers. STAB VIDA’s has an extensive experience of participating and coordinating national and European projects (FP6, FP7 and H2020), and is part of the European Consortium of PANA Project.